Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
07/28/2022* -- Results Q2 2022 -- 0.73 --
04/27/2022 -- Results Q1 2022 0.83 0.76 8.32%
02/09/2022 -- Results Q4 2021 0.69 0.65 7.18%
10/27/2021 -- Results Q3 2021 1.01 0.81 23.90%
07/28/2021 -- Results Q2 2021 0.78 0.33 135.8%
04/28/2021 -- Results Q1 2021 0.64 0.48 33.31%
02/03/2021 -- Results Q4 2020 0.64 0.48 32.00%
10/28/2020 -- Results Q3 2020 0.92 0.86 7.87%
*Estimated Date/Time

Earnings

Next Report Date 07/28/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 04/27/2022
Beat/Miss Upgrade
Return Since -1.24%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
URL https://www.gsk.com
Investor Relations URL https://www.gsk.com/en-gb/investors/
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 28, 2022 (est.)
Last Earnings Release Apr. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date May. 19, 2022

Dividends

Dividend Per Share (TTM) 2.166
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 3.369
Yield to Sector 2.323
Yield to Industry 1.329
Last Dividend Amt. 0.3496
Dividend Frequency Quarterly
Last Ex-Dividend Date May. 19, 2022
Yield (TTM) 4.46%
Forward Yield 4.46%
Payout Ratio 78.35%
Cash Payout Ratio 57.37%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-0.35%
1.81%
-2.96%
13.74%
29.20%
-17.66%
26.77%
3.25%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.67%
0.53%
-15.87%
33.20%
13.79%
35.65%
3.20%
19.72%
15.59%
--
-90.09%
150.3%
-64.61%
-74.06%
17.04%
35.62%
151.8%
--
--
--
--
28.09%
434.1%
143.1%
-46.35%
--
--
--
--
--
113.0%
56.35%
-41.82%
As of May 20, 2022.

Profile

Edit
In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
URL https://www.gsk.com
Investor Relations URL https://www.gsk.com/en-gb/investors/
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 28, 2022 (est.)
Last Earnings Release Apr. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date May. 19, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
PPH 20.04M USD 4.67%
CIG21506 115.42M USD 4.16%
VIRS 207651.0 USD 3.78%
DOXGX 2.580B USD 2.61%
GCOW 8.258M USD 1.94%
DOXBX 297.11M USD 1.87%
PAIGX 172.12M USD 1.41%
FGIKX 87.07M USD 1.06%
TTAI 570636.0 USD 1.02%
MNCSX 30.67M USD 0.90%
RODM 12.40M USD 0.82%
AVDE 6.683M USD 0.49%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter GSK Tweets